Importance of immature platelet fraction as a prognostic factor in myelodysplastic syndromes: a prospective observational study

MDS-IPF - MDS-IPF

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000057807

Enrollment

Registered

2025-05-09

Start date

2025-05-09

Completion date

Unknown

Last updated

2026-09-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

myelodysplastic syndrome

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Newly diagnosed MDS patients Age: 18 years or older IPSS-R: All risk groups IPF measured

Exclusion criteria

Exclusion criteria: patients with a history of previous treatment for MDS patients with serious comorbidities patients for whom it is difficult to obtain consent

Design outcomes

Primary

Measure	Time frame
Transition period to acute myeloid leukemia	—

Secondary

Measure	Time frame
Overall survival Hematological improvement Changes in transfusion dependency Correlation between IPF and AZA treatment response Incidence of adverse events	—

Countries

Japan

Contacts

Public ContactSATOSHI YAMASAKI

St.Marry Hospital Department of Hematology

sa-yamasaki@st-mary-med.or.jp0942353322

Outcome results